Repligen Corp (RGEN) 18.54 $RGEN
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Why Repligen Corporation Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 12:51PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life sciences company that...
Repligen Shares Up 20.0% Since SmarTrend's Buy Recommendation (RGEN)
Comtex SmarTrend(R) - Thu May 08, 10:02AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 weeks, Repligen has returned 19.96% as of today's recent price of $18.21.
Repligen Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
- Product Revenue Increases 20% to a Record $14.3 Million -
Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
GlobeNewswire - Tue May 06, 6:05AM CDT
Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr. Hunt was most recently President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. At Life Technologies, Mr. Hunt played a key role in the development and growth of the company's bioprocessing business, where he focused on expanding the upstream Gibco(R) cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt is an accomplished life sciences industry veteran who will oversee commercial and manufacturing operations for Repligen.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
Repligen to Report First Quarter 2014 Financial Results
GlobeNewswire - Fri Apr 25, 1:04PM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2014 financial results on Thursday, May 8, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended March 31, 2014.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 18, 11:54AM CDT
Many Americans didn't particularly enjoy this week as the dreaded April 15 federal tax deadline arrived. However, some health-care investors had reason to celebrate even if they had to pay up to Uncle Sam. Three stocks, in particular, enjoyed huge...
Repligen Corporation Set to Join the S&P SmallCap 600
PR Newswire - Tue Apr 15, 4:53PM CDT
Repligen Corporation (NASD:RGEN) will replace Hi-Tech Pharmacal Co., Inc. (NASD:HITK) in the S&P SmallCap 600 after the close of trading on Thursday, April 17. S&P SmallCap 600 constituent Akorn Inc. (NASD:AKRX) is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Top Gainers on the Move -- Research on Banco Bradesco, RadNet, Repligen, and B&G Foods
PR Newswire - Tue Apr 08, 9:17AM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 declined 1.08%, to finish the trading session at 1,845.04. The session witnessed selling pressure in the Consumer Discretionary, Financials, and Energy sectors that negatively impacted the broader market. A number of stocks saw large movements, including Banco Bradesco S.A. (NYSE: BBD), RadNet Inc. (NASDAQ: RDNT), Repligen Corp. (NASDAQ: RGEN) and B&G Foods Inc. (NYSE: BGS). Free technical research on BBD, RDNT, RGEN and BGS can be downloaded upon signing up at:
3 Stocks Spiking on Unusual Volume
at The Street - Tue Apr 08, 7:05AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Repligen Shares Down 10.8% Since SmarTrend's Sell Call (RGEN)
Comtex SmarTrend(R) - Mon Mar 31, 9:32AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on March 6th, 2014 at $14.02. In approximately 4 weeks, Repligen has returned 10.77% as of today's recent price of $12.51.
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS 45 cm diameter columns ("OPUS 45"
with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego.
Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Why Repligen Corporation Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 12:51PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life sciences company that...
Repligen Shares Up 20.0% Since SmarTrend's Buy Recommendation (RGEN)
Comtex SmarTrend(R) - Thu May 08, 10:02AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 weeks, Repligen has returned 19.96% as of today's recent price of $18.21.
Repligen Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
- Product Revenue Increases 20% to a Record $14.3 Million -
Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
GlobeNewswire - Tue May 06, 6:05AM CDT
Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr. Hunt was most recently President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. At Life Technologies, Mr. Hunt played a key role in the development and growth of the company's bioprocessing business, where he focused on expanding the upstream Gibco(R) cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt is an accomplished life sciences industry veteran who will oversee commercial and manufacturing operations for Repligen.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
Repligen to Report First Quarter 2014 Financial Results
GlobeNewswire - Fri Apr 25, 1:04PM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2014 financial results on Thursday, May 8, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended March 31, 2014.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 18, 11:54AM CDT
Many Americans didn't particularly enjoy this week as the dreaded April 15 federal tax deadline arrived. However, some health-care investors had reason to celebrate even if they had to pay up to Uncle Sam. Three stocks, in particular, enjoyed huge...
Repligen Corporation Set to Join the S&P SmallCap 600
PR Newswire - Tue Apr 15, 4:53PM CDT
Repligen Corporation (NASD:RGEN) will replace Hi-Tech Pharmacal Co., Inc. (NASD:HITK) in the S&P SmallCap 600 after the close of trading on Thursday, April 17. S&P SmallCap 600 constituent Akorn Inc. (NASD:AKRX) is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Top Gainers on the Move -- Research on Banco Bradesco, RadNet, Repligen, and B&G Foods
PR Newswire - Tue Apr 08, 9:17AM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 declined 1.08%, to finish the trading session at 1,845.04. The session witnessed selling pressure in the Consumer Discretionary, Financials, and Energy sectors that negatively impacted the broader market. A number of stocks saw large movements, including Banco Bradesco S.A. (NYSE: BBD), RadNet Inc. (NASDAQ: RDNT), Repligen Corp. (NASDAQ: RGEN) and B&G Foods Inc. (NYSE: BGS). Free technical research on BBD, RDNT, RGEN and BGS can be downloaded upon signing up at:
3 Stocks Spiking on Unusual Volume
at The Street - Tue Apr 08, 7:05AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Repligen Shares Down 10.8% Since SmarTrend's Sell Call (RGEN)
Comtex SmarTrend(R) - Mon Mar 31, 9:32AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on March 6th, 2014 at $14.02. In approximately 4 weeks, Repligen has returned 10.77% as of today's recent price of $12.51.
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS 45 cm diameter columns ("OPUS 45"
with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego. Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
